GlassScriptPhysician profile
Tehniat Haider
NPI 1396905782
$7,166.25
in general payments reported to CMS, 2019-2025
34 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $968 · 2021: $1,190 · 2022: $1,047 · 2023: $1,031 · 2024: $737 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,592 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.14 |
| Education | $253.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,021.81 | 2019-2025 | Enbrel, Evenity, Tavneos |
| Janssen Biotech, INC. | $898.76 | 2019-2025 | Tremfya |
| Abbvie INC. | $734.68 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $616.85 | 2019-2025 | |
| Pfizer INC. | $502.97 | 2019-2025 | |
| Ucb, INC. | $330.40 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $295.14 | 2019-2025 | Taltz, Zepbound, Mounjaro |
| Horizon Therapeutics Plc | $213.57 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $162.22 | 2019-2020 | |
| Glaxosmithkline, LLC. | $154.62 | 2021-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $147.69 | 2021-2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $135.71 | 2020-2024 | Orencia |
| Genzyme Corporation | $119.16 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $102.20 | 2022-2025 | Strensiq |
| Kyowa Kirin, INC. | $101.61 | 2023-2025 | Crysvita |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $94.66 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $74.60 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $45.95 | 2020-2024 | Vibativ |
| Pacira Therapeutics, INC. | $44.42 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $42.68 | 2023-2024 | Acthar |
| Ani Pharmaceuticals, INC. | $38.56 | 2022 | |
| Gilead Sciences, INC. | $37.75 | 2020-2021 | |
| Celgene Corporation | $32.47 | 2019 | |
| Radius Health, INC. | $32.04 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $24.73 | 2020 | |
| Mannkind Corporation | $22.87 | 2023 | Afrezza |
| Averitas Pharma INC. | $22.30 | 2024 | Qutenza |
| Avanir Pharmaceuticals, INC. | $18.55 | 2019 | |
| Sobi, INC | $18.27 | 2022 | |
| Organon LLC | $18.07 | 2024 | |
| Mylan Specialty L.P. | $17.04 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.68 | 2023 | Xifaxan |
| Kiniksa Pharmaceuticals International, Plc | $15.35 | 2024 | Arcalyst |
| Paratek Pharmaceuticals, INC. | $12.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tehniat Haider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.